• Yong-Zheng Fan, Yun-Li Duan, Chuan-Tao Chen, Yu Wang, and An-Ping Zhu.
• The 991st Hospital of Joint Logistic Support Force of People's Liberation Army, Xiangyang, China.
• Medicine (Baltimore). 2024 Jul 19; 103 (29): e38837e38837.

AbstractOpioids exert analgesic effects by agonizing opioid receptors and activating signaling pathways coupled to receptors such as G-protein and/or β-arrestin. Concomitant respiratory depression (RD) is a common clinical problem, and improvement of RD is usually achieved with specific antagonists such as naloxone; however, naloxone antagonizes opioid analgesia and may produce more unknown adverse effects. In recent years, researchers have used various methods to isolate opioid receptor-mediated analgesia and RD, with the aim of preserving opioid analgesia while attenuating RD. At present, the focus is mainly on the development of new opioids with weak respiratory inhibition or the use of non-opioid drugs to stimulate breathing. This review reports recent advances in novel opioid agents, such as mixed opioid receptor agonists, peripheral selective opioid receptor agonists, opioid receptor splice variant agonists, biased opioid receptor agonists, and allosteric modulators of opioid receptors, as well as in non-opioid agents, such as AMPA receptor modulators, 5-hydroxytryptamine receptor agonists, phosphodiesterase-4 inhibitors, and nicotinic acetylcholine receptor agonists.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

16 keywords...

hide…